Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical gentamicin for COL7A1 nonsense variant epidermolysis bullosa
ACTRN12626001182381Phase 2Completed
- Sponsor
- Sydney Children's Hospital
- Start
- Apr 2022
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa (EB) comparing Topical gentamicin wound with Vehicle control wound (2 arms). Primary endpoints: Proportion of wounds achieving first complete closure within 30 ± 7 days and Time to first complete wound closure. Started Apr 2022; status: completed.
02
Drugs
gentamicin
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on ACTRN12626001182381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001182381.